Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenstroms Macroglobulinemia- a single center real world retrospective analysis
Gupta, V.; Podder, D.; Saha, S.; Shah, B.; Ghosh, S.; Kumar, J.; Jacoby, A. P.; Nag, A.; Chattopadhyay, D.; Javed, R.; Rath, A.; Chakraborty, S.; Demde, R.; Vinarkar, S.; Parihar, M.; Zameer, L.; Mishra, D.; Chandy, M.; Nair, R.
Show abstract
Waldenstrom macroglobulinemia (WM) is a rare indolent neoplasm characterized by presence of more than 10% lymphoid cells in BM that exhibit plasmacytoid or plasma cell differentiation that secretes an IgM monoclonal protein. This is a retrospective analysis of 89 patients of WM that describes the clinical and laboratory characteristics, treatment patterns and outcome of patients of WM. The median age of the entire cophort was 66 years with male predominance (67.4%). Most common presentations were symptoms pertaining to anemia (77.5%) and constitutional symptoms (33.7%). Median bone marrow lymphoplasmacytic cells were 41%. Positivity for MYD88 and CXCR4 mutations were seen in 81.8% and 2.4% cases. BR was the most common regimen used (52.8%). Overall response rates were seen at 87.8%. Median overall survival, progression free survival and time to next treatment is 8.49 years, 2.15 years and 3.88 years. BR regimen was associated with highest event free survival.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.